Metabolics

 The Nutricia Learning Center features tools and educational resources for Metabolic Healthcare Professionals.

Healthcare Professional Tools

Flowcharts/Guidelines

Reference Library

  • PKU Periflex® Early Years (call Periflex® Infant in Europe)

    Select Clinical References for PKU Periflex Early Years

    • MacDonald A, et al. Specific prebiotics in a formula for infants with phenylketonuria. Mol Genet Metab. 2011;104 Suppl:S55-9. PubMed
  • Periflex® Junior Plus

    Select Clinical References for Periflex Junior Plus

    • Buist NRM, et al. A new amino acid mixture permits new approaches to the treatment of phenylketonuria. Acta Paediatr Suppl. 1994;407:75-7. PubMed
    • Cleary MA, et al. Randomised controlled trial of essential fatty acid supplementation in phenylketonuria. Eur J Clin Nutr. 2006;60(7):915-20. PubMed
  • PKU Maxamum®

    Select Clinical References for PKU Maxamum (previously named XPhe Maxamum)

    • Brown MC, et al Economic impact of feeding a phenylalanine-restricted diet to adults with previously untreated phenylketonuria. J Intell Disabil Res. 1999; 43:30-7. PubMed
    • Cleary MA, et al. Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. J Pediatr. 1995; 127:251-255. PubMed
    • Wardley BL, Taitz LS. Clinical trial of a concentrated amino acid formula for older patients with phenylketouria (Maxamum XP). Eur J Clin Nutr. 1988; 42:81-86. PubMed
  • Phlexy-10®

    Select Clinical References for Phlexy-10

    • MacDonald A, et al. Protein substitutes for PKU: What’s new? J Inherit Metab Dis. 2004; 27:363-371. PubMed
    • Moats RA, et al. Brain phenylalanine concentrations in phenylketonuria: Research and treatment of adults. Pediatrics. 2003;112(6): 1575-9. PubMed
    • Rohr FJ, et al. Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria. J Inherit Metab Dis. 2001; 24:623-630. PubMed
  • PhenylAde® PheBLOC™ LNAA

    Select Clinical References for PhenylAde PheBLOC LNAA

    • Yano S, et al. Melatonin and dopamine as biomarkers to optimize treatment in phenylketonuria: effects of tryptophan and tyrosine supplementation. J Pediatr. 2014;165:184-9. PubMed
  • GlutarAde® Junior

    Select Clinical References for GlutarAde Junior

    • Stauss KA, et al. Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: focus on cerebral amino acid influx. Mol Genet Metab. 2011;104(1-2):93-106. PubMed
    • Strauss, KA et al. Glutaric acidemia type 1: Treatment and outcome of 168 patients over three decades. Mol Genet Metab. 2020;131:325-40. PubMed
  • Complex® MSD Products

    Select Clinical References for Complex MSD Products

    • Strauss KA, et al. Classical maple syrup urine disease and brain development: principles of management and formula design. Mol Genet Metab. 2010;99(4):333-45. PubMed
    • Strauss KA, et al. Branched-chain α-ketoacid dehydrogenase deficiency (maple syrup urine disease): Treatment, biomarkers, and outcomes. Mol Genet Metab. 2020;129:193-206. PubMed
  • Monogen®

    Select Clinical References for Monogen

    • Cormack, BE et al. Use of Monogen for pediatric postoperative chylothorax. Ann Thorac Surg. 2004; 77(1):301-5. PubMed
    • Ficicioglu C, et al. Very long-chain acyl-CoA dehydrogenase deficiency: The effects of accidental fat loading in a a patient detected through newborn screening. J Inherit Metab Dis. 2009;32 Suppl 1:S187-90. PubMed
    • Lessen R. Use of Skim Breast Milk for an Infant with Chylothorax. ICAN (2009); 1 (6):303-10. Sage Journals
    • Ng PC, et al. Deceptive hyperbilirubinaemia in a newborn with familial lipoprotein lipase deficiency. J Paediatr Child Health. 2001;37:314-6. PubMed